As a novel anti-cancer molecule, icaritin has been shown to suppress hepatocellular carcinoma (HCC) initiation and malignant growth through the Interleukin-6/Janus-activated kinases 2/Signal transducer and activator of transcription 3 pathway [1]. Here, IL6 is linked to hepatocellular carcinoma.